The recruited patients with T2D received antidiabetic treatments, such as metformin, sodium-glucose cotransporter-2 inhibitors (SGLT-2Is), and glucagon-like peptide-1 receptor agonists (GLP-1RAs), which may have roles in decreasing BMI. Here, SLC5A2 is linked to type 2 diabetes mellitus.